Target Information
| Target General Information | Top | |||||
|---|---|---|---|---|---|---|
| Target ID |
T71905
(Former ID: TTDS00216)
|
|||||
| Target Name |
Bacterial 16S ribosomal RNA (Bact 16S rRNA)
|
|||||
| Synonyms |
RrnS; Plastid 16S rRNA; 16S rRNA
Click to Show/Hide
|
|||||
| Gene Name |
NO-GeName
|
|||||
| Target Type |
Successful target
|
[1] | ||||
| Disease | [+] 3 Target-related Diseases | + | ||||
| 1 | Acute/subacute hepatic failure [ICD-11: DB91] | |||||
| 2 | Alcoholic liver disease [ICD-11: DB94] | |||||
| 3 | Bacterial infection [ICD-11: 1A00-1C4Z] | |||||
| UniProt ID | ||||||
| Drugs and Modes of Action | Top | |||||
|---|---|---|---|---|---|---|
| Approved Drug(s) | [+] 1 Approved Drugs | + | ||||
| 1 | Framycetin | Drug Info | Approved | Alcoholic cirrhosis of liver | [2], [3] | |
| Clinical Trial Drug(s) | [+] 2 Clinical Trial Drugs | + | ||||
| 1 | Oxazolidinones | Drug Info | Phase 2 | Gram-positive bacterial infection | [4] | |
| 2 | Apramycin | Drug Info | Phase 1 | Gram-negative bacterial infection | [5] | |
| Mode of Action | [+] 2 Modes of Action | + | ||||
| Binder | [+] 1 Binder drugs | + | ||||
| 1 | Framycetin | Drug Info | [1] | |||
| Inhibitor | [+] 8 Inhibitor drugs | + | ||||
| 1 | Oxazolidinones | Drug Info | [6] | |||
| 2 | Apramycin | Drug Info | [7] | |||
| 3 | Aminodeoxykanamycin | Drug Info | [7] | |||
| 4 | Butirosin B | Drug Info | [7] | |||
| 5 | G418 | Drug Info | [7] | |||
| 6 | Hygromycin B | Drug Info | [7] | |||
| 7 | Neamine | Drug Info | [7] | |||
| 8 | Ribostamycin | Drug Info | [7] | |||
| Drug Property Profile of Target | Top | |
|---|---|---|
| (1) Molecular Weight (mw) based Drug Clustering | (2) Octanol/Water Partition Coefficient (xlogp) based Drug Clustering | |
|
|
||
| (3) Hydrogen Bond Donor Count (hbonddonor) based Drug Clustering | (4) Hydrogen Bond Acceptor Count (hbondacc) based Drug Clustering | |
|
|
||
| (5) Rotatable Bond Count (rotbonds) based Drug Clustering | (6) Topological Polar Surface Area (polararea) based Drug Clustering | |
|
|
||
| "RO5" indicates the cutoff set by lipinski's rule of five; "D123AB" colored in GREEN denotes the no violation of any cutoff in lipinski's rule of five; "D123AB" colored in PURPLE refers to the violation of only one cutoff in lipinski's rule of five; "D123AB" colored in BLACK represents the violation of more than one cutoffs in lipinski's rule of five | ||
| Co-Targets | Top | |||||
|---|---|---|---|---|---|---|
| Co-Targets | ||||||
| Target-Related Models and Studies | Top | |||||
|---|---|---|---|---|---|---|
| Target Validation | ||||||
| References | Top | |||||
|---|---|---|---|---|---|---|
| REF 1 | Antistaphylococcal activity of gentamicin. Minerva Med. 1975 Dec 8;66(84):4505-26. | |||||
| REF 2 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 709). | |||||
| REF 3 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 060304. | |||||
| REF 4 | ClinicalTrials.gov (NCT00646958) Safety and Efficacy Study of Oxazolidinones to Treat Uncomplicated Skin Infections. U.S. National Institutes of Health. | |||||
| REF 5 | ClinicalTrials.gov (NCT04105205) First-In-Human Study of Apramycin. U.S. National Institutes of Health. | |||||
| REF 6 | Ribosomal RNA is the target for oxazolidinones, a novel class of translational inhibitors. RNA. 1999 Jul;5(7):939-46. | |||||
| REF 7 | RNA as a target for small molecules. Curr Opin Chem Biol. 2000 Dec;4(6):678-86. | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.